Curis (NASDAQ:CRIS) Releases Earnings Results

Curis (NASDAQ:CRIS) issued its earnings results on Tuesday. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.92), FiscalAI reports.

Curis Stock Down 0.1%

NASDAQ CRIS traded down $0.00 during trading on Tuesday, hitting $0.55. The stock had a trading volume of 287,114 shares, compared to its average volume of 574,140. The company has a market capitalization of $22.00 million, a PE ratio of -0.46 and a beta of 3.08. The firm has a 50 day moving average price of $0.71 and a 200 day moving average price of $0.99. Curis has a twelve month low of $0.49 and a twelve month high of $3.13.

Analyst Ratings Changes

CRIS has been the subject of a number of recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curis in a research note on Monday, April 20th. HC Wainwright reissued a “buy” rating and set a $17.00 price objective on shares of Curis in a research report on Friday, March 20th. Finally, Wall Street Zen raised Curis to a “hold” rating in a research report on Saturday, March 28th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $17.00.

Hedge Funds Weigh In On Curis

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC lifted its stake in Curis by 71.8% during the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 10,586 shares during the last quarter. XTX Topco Ltd purchased a new stake in Curis during the fourth quarter worth approximately $26,000. Squarepoint Ops LLC lifted its stake in Curis by 46.2% during the fourth quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 27,343 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in Curis by 2,883,237.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock worth $228,000 after purchasing an additional 230,659 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Curis by 37.3% during the fourth quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock worth $238,000 after purchasing an additional 65,404 shares during the last quarter. Hedge funds and other institutional investors own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.